Qiagen (NYSE:QGEN) Shares Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp increased its position in shares of Qiagen (NYSE:QGEN) by 37.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,400 shares of the company’s stock after acquiring an additional 3,400 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Qiagen were worth $552,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of QGEN. Groupama Asset Managment lifted its position in shares of Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company’s stock worth $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company’s stock worth $1,127,470,000 after buying an additional 2,202,040 shares during the period. Wellington Management Group LLP lifted its holdings in Qiagen by 2.5% during the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company’s stock worth $970,534,000 after buying an additional 531,362 shares in the last quarter. Vanguard Group Inc. boosted its position in Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company’s stock valued at $397,937,000 after buying an additional 77,119 shares during the period. Finally, Norges Bank purchased a new position in Qiagen in the 4th quarter valued at approximately $181,529,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several analyst reports. Redburn Atlantic cut Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. UBS Group decreased their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Robert W. Baird upped their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Finally, StockNews.com upgraded shares of Qiagen from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Qiagen currently has an average rating of “Hold” and a consensus price target of $48.42.

Qiagen Price Performance

Shares of QGEN opened at $42.65 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The firm has a 50-day simple moving average of $40.97 and a 200-day simple moving average of $41.81. The company has a market capitalization of $9.48 billion, a price-to-earnings ratio of 118.76, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The company’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted $0.44 EPS. On average, equities research analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.